Search

Your search keyword '"Blank, Stephanie V."' showing total 509 results
Start Over Author "Blank, Stephanie V."
509 results on '"Blank, Stephanie V."'

16. Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.

Author

Thomes Pepin, Jessica, primary, Chon, Hye Sook, additional, Sundborg, Michael J., additional, Gold, Michael A., additional, Kim, Byoung-Gie, additional, Blank, Stephanie V., additional, Liu, Ji-Hong, additional, McCollum, Michael, additional, Mori, Masahiko, additional, Moore, Kathleen N., additional, Rivera Diaz, Julian, additional, de Padua, Charles Andreé Joseph, additional, Martínez-García, Jerónimo, additional, Papadimitriou, Christos, additional, Gri an, Karin, additional, Póka, Róbert, additional, Kowgier, Matthew, additional, Oscroft, Emma, additional, Van Nieuwenhuysen, Els, additional, and Westin, Shannon Neville, additional

Published
2024
Full Text
View/download PDF

17. Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by BRCA1/BRCA2 mutation (BRCAm) status.

Author

Van Nieuwenhuysen, Els, primary, Baurain, Jean-Francois, additional, Chon, Hye Sook, additional, Thomes Pepin, Jessica, additional, Sundborg, Michael J., additional, Gold, Michael A., additional, Kim, Byoung-Gie, additional, Blank, Stephanie V., additional, Liu, Ji-Hong, additional, McCollum, Michael, additional, Mori, Masahiko, additional, Jonuškienė, Goda, additional, Moore, Kathleen N., additional, Novák, Zoltán, additional, Ramos, Pedro, additional, de Padua, Charles Andreé Joseph, additional, Gil-Martin, Marta, additional, Kowgier, Matthew, additional, del Rosario, Paula Michelle, additional, and Westin, Shannon Neville, additional

Published
2024
Full Text
View/download PDF

18. Long-term survival outcomes for hormonal therapy in premenopausal patients with clinical stage I endometrial cancer.

Author

Suzuki, Yukio, primary, Huang, Yongmei, additional, Havrilesky, Laura J, additional, Blank, Stephanie V., additional, Elkin, Elena B., additional, Melamed, Alexander, additional, Ferris, Jennifer S., additional, Saji, Haruya, additional, Miyagi, Etsuko, additional, Kong, Chung Yin, additional, Myers, Evan R., additional, and Wright, Jason Dennis, additional

Published
2024
Full Text
View/download PDF

21. Sexual Harassment, Abuse, and Discrimination in Obstetrics and Gynecology

Author

Gupta, Ankita, primary, Thompson, Jennifer C., additional, Ringel, Nancy E., additional, Kim-Fine, Shunaha, additional, Ferguson, Lindsay A., additional, Blank, Stephanie V., additional, Iglesia, Cheryl B., additional, Balk, Ethan M., additional, Secord, Angeles Alvarez, additional, Hines, Jeffrey F., additional, Brown, Jubilee, additional, and Grimes, Cara L., additional

Published
2024
Full Text
View/download PDF

22. Supplementary Figure S4 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial

Author

Landen, Charles N., primary, Molinero, Luciana, primary, Hamidi, Habib, primary, Sehouli, Jalid, primary, Miller, Austin, primary, Moore, Kathleen N., primary, Taskiran, Cagatay, primary, Bookman, Michael, primary, Lindemann, Kristina, primary, Anderson, Charles, primary, Berger, Regina, primary, Myers, Tashanna, primary, Beiner, Mario, primary, Reid, Thomas, primary, Van Nieuwenhuysen, Els, primary, Green, Andrew, primary, Okamoto, Aikou, primary, Aghajanian, Carol, primary, Thaker, Premal H., primary, Blank, Stephanie V., primary, Khor, Victor K., primary, Chang, Ching-Wei, primary, Lin, Yvonne G., primary, and Pignata, Sandro, primary

Published
2024
Full Text
View/download PDF

23. Data from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial

Author

Landen, Charles N., primary, Molinero, Luciana, primary, Hamidi, Habib, primary, Sehouli, Jalid, primary, Miller, Austin, primary, Moore, Kathleen N., primary, Taskiran, Cagatay, primary, Bookman, Michael, primary, Lindemann, Kristina, primary, Anderson, Charles, primary, Berger, Regina, primary, Myers, Tashanna, primary, Beiner, Mario, primary, Reid, Thomas, primary, Van Nieuwenhuysen, Els, primary, Green, Andrew, primary, Okamoto, Aikou, primary, Aghajanian, Carol, primary, Thaker, Premal H., primary, Blank, Stephanie V., primary, Khor, Victor K., primary, Chang, Ching-Wei, primary, Lin, Yvonne G., primary, and Pignata, Sandro, primary

Published
2024
Full Text
View/download PDF

27. Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression

Author

Frey, Melissa K., Lee, Sarah S, Gerber, Deanna, Schwartz, Zachary P., Martineau, Jessica, Lutz, Kathleen, Reese, Erin, Dalton, Emily, Olsen, Annie, Girdler, Julia, Pothuri, Bhavana, Boyd, Leslie, Curtin, John P., Levine, Douglas A., and Blank, Stephanie V.

Published
2020
Full Text
View/download PDF

29. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer.

Author

Couch, Fergus J, Kuchenbaecker, Karoline B, Michailidou, Kyriaki, Mendoza-Fandino, Gustavo A, Nord, Silje, Lilyquist, Janna, Olswold, Curtis, Hallberg, Emily, Agata, Simona, Ahsan, Habibul, Aittomäki, Kristiina, Ambrosone, Christine, Andrulis, Irene L, Anton-Culver, Hoda, Arndt, Volker, Arun, Banu K, Arver, Brita, Barile, Monica, Barkardottir, Rosa B, Barrowdale, Daniel, Beckmann, Lars, Beckmann, Matthias W, Benitez, Javier, Blank, Stephanie V, Blomqvist, Carl, Bogdanova, Natalia V, Bojesen, Stig E, Bolla, Manjeet K, Bonanni, Bernardo, Brauch, Hiltrud, Brenner, Hermann, Burwinkel, Barbara, Buys, Saundra S, Caldes, Trinidad, Caligo, Maria A, Canzian, Federico, Carpenter, Jane, Chang-Claude, Jenny, Chanock, Stephen J, Chung, Wendy K, Claes, Kathleen BM, Cox, Angela, Cross, Simon S, Cunningham, Julie M, Czene, Kamila, Daly, Mary B, Damiola, Francesca, Darabi, Hatef, de la Hoya, Miguel, Devilee, Peter, Diez, Orland, Ding, Yuan C, Dolcetti, Riccardo, Domchek, Susan M, Dorfling, Cecilia M, Dos-Santos-Silva, Isabel, Dumont, Martine, Dunning, Alison M, Eccles, Diana M, Ehrencrona, Hans, Ekici, Arif B, Eliassen, Heather, Ellis, Steve, Fasching, Peter A, Figueroa, Jonine, Flesch-Janys, Dieter, Försti, Asta, Fostira, Florentia, Foulkes, William D, Friebel, Tara, Friedman, Eitan, Frost, Debra, Gabrielson, Marike, Gammon, Marilie D, Ganz, Patricia A, Gapstur, Susan M, Garber, Judy, Gaudet, Mia M, Gayther, Simon A, Gerdes, Anne-Marie, Ghoussaini, Maya, Giles, Graham G, Glendon, Gord, Godwin, Andrew K, Goldberg, Mark S, Goldgar, David E, González-Neira, Anna, Greene, Mark H, Gronwald, Jacek, Guénel, Pascal, Gunter, Marc, Haeberle, Lothar, Haiman, Christopher A, Hamann, Ute, Hansen, Thomas VO, Hart, Steven, Healey, Sue, Heikkinen, Tuomas, Henderson, Brian E, and Herzog, Josef

Subjects
Chromosomes, Human, Pair 2, Humans, Breast Neoplasms, Genetic Predisposition to Disease, Cyclophilins, tRNA Methyltransferases, BRCA1 Protein, Receptors, Estrogen, Risk Factors, Genotype, Heterozygote, Mutation, Polymorphism, Single Nucleotide, Female, Genome-Wide Association Study, Chromosomes, Human, Pair 2, Receptors, Estrogen, Polymorphism, Single Nucleotide, Breast Cancer, Cancer, Prevention, Genetics, Human Genome, 2.1 Biological and endogenous factors
Abstract

Common variants in 94 loci have been associated with breast cancer including 15 loci with genome-wide significant associations (P

Published
2016

32. Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199

Author

Sherman, Mark E, Piedmonte, Marion, Mai, Phuong L, Ioffe, Olga B, Ronnett, Brigitte M, Van Le, Linda, Ivanov, Iouri, Bell, Maria C, Blank, Stephanie V, DiSilvestro, Paul, Hamilton, Chad A, Tewari, Krishnansu S, Wakeley, Katie, Kauff, Noah D, Yamada, S Diane, Rodriguez, Gustavo, Skates, Steven J, Alberts, David S, Walker, Joan L, Minasian, Lori, Lu, Karen, and Greene, Mark H

Subjects
Aging, Ovarian Cancer, Cancer, Prevention, Rare Diseases, Clinical Research, Breast Cancer, Patient Safety, Adult, Biomarkers, Tumor, Breast Neoplasms, CA-125 Antigen, Fallopian Tube Neoplasms, Female, Genes, BRCA1, Genes, BRCA2, Genetic Predisposition to Disease, Humans, Middle Aged, Mutation, Neoplasm Invasiveness, Neoplasms, Unknown Primary, Ovarian Neoplasms, Ovariectomy, Risk Factors, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeRisk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovarian/tubal and breast cancers among BRCA1/2 mutation carriers. Uncertainties persist regarding potential benefits of RRSO among high-risk noncarriers, optimal surgical age, and anatomic origin of clinically occult cancers detected at surgery. To address these topics, we analyzed surgical treatment arm results from Gynecologic Oncology Group Protocol-0199 (GOG-0199), the National Ovarian Cancer Prevention and Early Detection Study.Participants and methodsThis analysis included asymptomatic high-risk women age ≥ 30 years who elected RRSO at enrollment. Women provided risk factor data and underwent preoperative cancer antigen 125 (CA-125) serum testing and transvaginal ultrasound (TVU). RRSO specimens were processed according to a standardized tissue processing protocol and underwent central pathology panel review. Research-based BRCA1/2 mutation testing was performed when a participant's mutation status was unknown at enrollment. Relationships between participant characteristics and diagnostic findings were assessed using univariable statistics and multivariable logistic regression.ResultsInvasive or intraepithelial ovarian/tubal/peritoneal neoplasms were detected in 25 (2.6%) of 966 RRSOs (BRCA1 mutation carriers, 4.6%; BRCA2 carriers, 3.5%; and noncarriers, 0.5%; P < .001). In multivariable models, positive BRCA1/2 mutation status (P = .0056), postmenopausal status (P = .0023), and abnormal CA-125 levels and/or TVU examinations (P < .001) were associated with detection of clinically occult neoplasms at RRSO. For 387 women with negative BRCA1/2 mutation testing and normal CA-125 levels, findings at RRSO were benign.ConclusionClinically occult cancer was detected among 2.6% of high-risk women undergoing RRSO. BRCA1/2 mutation, postmenopausal status, and abnormal preoperative CA-125 and/or TVU were associated with cancer detection at RRSO. These data can inform management decisions among women at high risk of ovarian/tubal cancer.

Published
2014

33. Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial

Author

Swisher, Elizabeth M., primary, Rayes, Nadine, additional, Bowen, Deborah, additional, Peterson, Christine B., additional, Norquist, Barbara M., additional, Coffin, Tara, additional, Gavin, Kathleen, additional, Polinsky, Deborah, additional, Crase, Jamie, additional, Bakkum-Gamez, Jamie N., additional, Blank, Stephanie V., additional, Munsell, Mark F., additional, Nebgen, Denise, additional, Fleming, Gini F., additional, Olopade, Olufunmilayo I., additional, Law, Sherman, additional, Zhou, Alicia, additional, Levine, Douglas A., additional, D’Andrea, Alan, additional, and Lu, Karen H., additional

Published
2023
Full Text
View/download PDF

35. Web-based tool for cancer family history collection: A prospective randomized controlled trial

Author

Frey, Melissa K., primary, Ahsan, Muhammad Danyal, additional, Webster, Emily, additional, Levi, Sarah R., additional, Brewer, Jesse T., additional, Lin, Jenny, additional, Blank, Stephanie V., additional, Krinsky, Hannah, additional, Nchako, Corbyn, additional, Wolfe, Isabel, additional, Thomas, Charlene, additional, Christos, Paul, additional, Cantillo, Evelyn, additional, Chapman-Davis, Eloise, additional, Holcomb, Kevin, additional, and Sharaf, Ravi N., additional

Published
2023
Full Text
View/download PDF

39. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.

Author

Westin, Shannon N., Moore, Kathleen, Chon, Hye Sook, Lee, Jung-Yun, Thomes Pepin, Jessica, Sundborg, Michael, Shai, Ayelet, de la Garza, Joseph, Nishio, Shin, Gold, Michael A., Wang, Ke, McIntyre, Kristi, Tillmanns, Todd D., Blank, Stephanie V., Liu, Ji-Hong, McCollum, Michael, Contreras Mejia, Fernando, Nishikawa, Tadaaki, Pennington, Kathryn, and Novak, Zoltan

Published
2024
Full Text
View/download PDF

43. Supplementary Figure S2 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial

Author

Landen, Charles N., primary, Molinero, Luciana, primary, Hamidi, Habib, primary, Sehouli, Jalid, primary, Miller, Austin, primary, Moore, Kathleen N., primary, Taskiran, Cagatay, primary, Bookman, Michael, primary, Lindemann, Kristina, primary, Anderson, Charles, primary, Berger, Regina, primary, Myers, Tashanna, primary, Beiner, Mario, primary, Reid, Thomas, primary, Van Nieuwenhuysen, Els, primary, Green, Andrew, primary, Okamoto, Aikou, primary, Aghajanian, Carol, primary, Thaker, Premal H., primary, Blank, Stephanie V., primary, Khor, Victor K., primary, Chang, Ching-Wei, primary, Lin, Yvonne G., primary, and Pignata, Sandro, primary

Published
2023
Full Text
View/download PDF

44. Data from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial

Author

Landen, Charles N., primary, Molinero, Luciana, primary, Hamidi, Habib, primary, Sehouli, Jalid, primary, Miller, Austin, primary, Moore, Kathleen N., primary, Taskiran, Cagatay, primary, Bookman, Michael, primary, Lindemann, Kristina, primary, Anderson, Charles, primary, Berger, Regina, primary, Myers, Tashanna, primary, Beiner, Mario, primary, Reid, Thomas, primary, Van Nieuwenhuysen, Els, primary, Green, Andrew, primary, Okamoto, Aikou, primary, Aghajanian, Carol, primary, Thaker, Premal H., primary, Blank, Stephanie V., primary, Khor, Victor K., primary, Chang, Ching-Wei, primary, Lin, Yvonne G., primary, and Pignata, Sandro, primary

Published
2023
Full Text
View/download PDF

47. Data from Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction

Author

Antoniou, Antonis C., primary, Beesley, Jonathan, primary, McGuffog, Lesley, primary, Sinilnikova, Olga M., primary, Healey, Sue, primary, Neuhausen, Susan L., primary, Ding, Yuan Chun, primary, Rebbeck, Timothy R., primary, Weitzel, Jeffrey N., primary, Lynch, Henry T., primary, Isaacs, Claudine, primary, Ganz, Patricia A., primary, Tomlinson, Gail, primary, Olopade, Olufunmilayo I., primary, Couch, Fergus J., primary, Wang, Xianshu, primary, Lindor, Noralane M., primary, Pankratz, Vernon S., primary, Radice, Paolo, primary, Manoukian, Siranoush, primary, Peissel, Bernard, primary, Zaffaroni, Daniela, primary, Barile, Monica, primary, Viel, Alessandra, primary, Allavena, Anna, primary, Dall'Olio, Valentina, primary, Peterlongo, Paolo, primary, Szabo, Csilla I., primary, Zikan, Michal, primary, Claes, Kathleen, primary, Poppe, Bruce, primary, Foretova, Lenka, primary, Mai, Phuong L., primary, Greene, Mark H., primary, Rennert, Gad, primary, Lejbkowicz, Flavio, primary, Glendon, Gord, primary, Ozcelik, Hilmi, primary, Andrulis, Irene L., primary, Thomassen, Mads, primary, Gerdes, Anne-Marie, primary, Sunde, Lone, primary, Cruger, Dorthe, primary, Birk Jensen, Uffe, primary, Caligo, Maria, primary, Friedman, Eitan, primary, Kaufman, Bella, primary, Laitman, Yael, primary, Milgrom, Roni, primary, Dubrovsky, Maya, primary, Cohen, Shimrit, primary, Borg, Ake, primary, Jernström, Helena, primary, Lindblom, Annika, primary, Rantala, Johanna, primary, Stenmark-Askmalm, Marie, primary, Melin, Beatrice, primary, Nathanson, Kate, primary, Domchek, Susan, primary, Jakubowska, Ania, primary, Lubinski, Jan, primary, Huzarski, Tomasz, primary, Osorio, Ana, primary, Lasa, Adriana, primary, Durán, Mercedes, primary, Tejada, Maria-Isabel, primary, Godino, Javier, primary, Benitez, Javier, primary, Hamann, Ute, primary, Kriege, Mieke, primary, Hoogerbrugge, Nicoline, primary, van der Luijt, Rob B., primary, Asperen, Christi J. van, primary, Devilee, Peter, primary, Meijers-Heijboer, E.J., primary, Blok, Marinus J., primary, Aalfs, Cora M., primary, Hogervorst, Frans, primary, Rookus, Matti, primary, Cook, Margaret, primary, Oliver, Clare, primary, Frost, Debra, primary, Conroy, Don, primary, Evans, D. Gareth, primary, Lalloo, Fiona, primary, Pichert, Gabriella, primary, Davidson, Rosemarie, primary, Cole, Trevor, primary, Cook, Jackie, primary, Paterson, Joan, primary, Hodgson, Shirley, primary, Morrison, Patrick J., primary, Porteous, Mary E., primary, Walker, Lisa, primary, Kennedy, M. John, primary, Dorkins, Huw, primary, Peock, Susan, primary, Godwin, Andrew K., primary, Stoppa-Lyonnet, Dominique, primary, de Pauw, Antoine, primary, Mazoyer, Sylvie, primary, Bonadona, Valérie, primary, Lasset, Christine, primary, Dreyfus, Hélène, primary, Leroux, Dominique, primary, Hardouin, Agnès, primary, Berthet, Pascaline, primary, Faivre, Laurence, primary, Loustalot, Catherine, primary, Noguchi, Tetsuro, primary, Sobol, Hagay, primary, Rouleau, Etienne, primary, Nogues, Catherine, primary, Frénay, Marc, primary, Vénat-Bouvet, Laurence, primary, Hopper, John L., primary, Daly, Mary B., primary, Terry, Mary B., primary, John, Esther M., primary, Buys, Saundra S., primary, Yassin, Yosuf, primary, Miron, Alexander, primary, Goldgar, David, primary, Singer, Christian F., primary, Dressler, Anne Catharina, primary, Gschwantler-Kaulich, Daphne, primary, Pfeiler, Georg, primary, Hansen, Thomas V.O., primary, Jønson, Lars, primary, Agnarsson, Bjarni A., primary, Kirchhoff, Tomas, primary, Offit, Kenneth, primary, Devlin, Vincent, primary, Dutra-Clarke, Ana, primary, Piedmonte, Marion, primary, Rodriguez, Gustavo C., primary, Wakeley, Katie, primary, Boggess, John F., primary, Basil, Jack, primary, Schwartz, Peter E., primary, Blank, Stephanie V., primary, Toland, Amanda Ewart, primary, Montagna, Marco, primary, Casella, Cinzia, primary, Imyanitov, Evgeny, primary, Tihomirova, Laima, primary, Blanco, Ignacio, primary, Lazaro, Conxi, primary, Ramus, Susan J., primary, Sucheston, Lara, primary, Karlan, Beth Y., primary, Gross, Jenny, primary, Schmutzler, Rita, primary, Wappenschmidt, Barbara, primary, Engel, Christoph, primary, Meindl, Alfons, primary, Lochmann, Magdalena, primary, Arnold, Norbert, primary, Heidemann, Simone, primary, Varon-Mateeva, Raymonda, primary, Niederacher, Dieter, primary, Sutter, Christian, primary, Deissler, Helmut, primary, Gadzicki, Dorothea, primary, Preisler-Adams, Sabine, primary, Kast, Karin, primary, Schönbuchner, Ines, primary, Caldes, Trinidad, primary, de la Hoya, Miguel, primary, Aittomäki, Kristiina, primary, Nevanlinna, Heli, primary, Simard, Jacques, primary, Spurdle, Amanda B., primary, Holland, Helene, primary, Chen, Xiaoqing, primary, Platte, Radka, primary, Chenevix-Trench, Georgia, primary, and Easton, Douglas F., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Methods, Tables 1-3, Figure 1 from Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction

Author

Antoniou, Antonis C., primary, Beesley, Jonathan, primary, McGuffog, Lesley, primary, Sinilnikova, Olga M., primary, Healey, Sue, primary, Neuhausen, Susan L., primary, Ding, Yuan Chun, primary, Rebbeck, Timothy R., primary, Weitzel, Jeffrey N., primary, Lynch, Henry T., primary, Isaacs, Claudine, primary, Ganz, Patricia A., primary, Tomlinson, Gail, primary, Olopade, Olufunmilayo I., primary, Couch, Fergus J., primary, Wang, Xianshu, primary, Lindor, Noralane M., primary, Pankratz, Vernon S., primary, Radice, Paolo, primary, Manoukian, Siranoush, primary, Peissel, Bernard, primary, Zaffaroni, Daniela, primary, Barile, Monica, primary, Viel, Alessandra, primary, Allavena, Anna, primary, Dall'Olio, Valentina, primary, Peterlongo, Paolo, primary, Szabo, Csilla I., primary, Zikan, Michal, primary, Claes, Kathleen, primary, Poppe, Bruce, primary, Foretova, Lenka, primary, Mai, Phuong L., primary, Greene, Mark H., primary, Rennert, Gad, primary, Lejbkowicz, Flavio, primary, Glendon, Gord, primary, Ozcelik, Hilmi, primary, Andrulis, Irene L., primary, Thomassen, Mads, primary, Gerdes, Anne-Marie, primary, Sunde, Lone, primary, Cruger, Dorthe, primary, Birk Jensen, Uffe, primary, Caligo, Maria, primary, Friedman, Eitan, primary, Kaufman, Bella, primary, Laitman, Yael, primary, Milgrom, Roni, primary, Dubrovsky, Maya, primary, Cohen, Shimrit, primary, Borg, Ake, primary, Jernström, Helena, primary, Lindblom, Annika, primary, Rantala, Johanna, primary, Stenmark-Askmalm, Marie, primary, Melin, Beatrice, primary, Nathanson, Kate, primary, Domchek, Susan, primary, Jakubowska, Ania, primary, Lubinski, Jan, primary, Huzarski, Tomasz, primary, Osorio, Ana, primary, Lasa, Adriana, primary, Durán, Mercedes, primary, Tejada, Maria-Isabel, primary, Godino, Javier, primary, Benitez, Javier, primary, Hamann, Ute, primary, Kriege, Mieke, primary, Hoogerbrugge, Nicoline, primary, van der Luijt, Rob B., primary, Asperen, Christi J. van, primary, Devilee, Peter, primary, Meijers-Heijboer, E.J., primary, Blok, Marinus J., primary, Aalfs, Cora M., primary, Hogervorst, Frans, primary, Rookus, Matti, primary, Cook, Margaret, primary, Oliver, Clare, primary, Frost, Debra, primary, Conroy, Don, primary, Evans, D. Gareth, primary, Lalloo, Fiona, primary, Pichert, Gabriella, primary, Davidson, Rosemarie, primary, Cole, Trevor, primary, Cook, Jackie, primary, Paterson, Joan, primary, Hodgson, Shirley, primary, Morrison, Patrick J., primary, Porteous, Mary E., primary, Walker, Lisa, primary, Kennedy, M. John, primary, Dorkins, Huw, primary, Peock, Susan, primary, Godwin, Andrew K., primary, Stoppa-Lyonnet, Dominique, primary, de Pauw, Antoine, primary, Mazoyer, Sylvie, primary, Bonadona, Valérie, primary, Lasset, Christine, primary, Dreyfus, Hélène, primary, Leroux, Dominique, primary, Hardouin, Agnès, primary, Berthet, Pascaline, primary, Faivre, Laurence, primary, Loustalot, Catherine, primary, Noguchi, Tetsuro, primary, Sobol, Hagay, primary, Rouleau, Etienne, primary, Nogues, Catherine, primary, Frénay, Marc, primary, Vénat-Bouvet, Laurence, primary, Hopper, John L., primary, Daly, Mary B., primary, Terry, Mary B., primary, John, Esther M., primary, Buys, Saundra S., primary, Yassin, Yosuf, primary, Miron, Alexander, primary, Goldgar, David, primary, Singer, Christian F., primary, Dressler, Anne Catharina, primary, Gschwantler-Kaulich, Daphne, primary, Pfeiler, Georg, primary, Hansen, Thomas V.O., primary, Jønson, Lars, primary, Agnarsson, Bjarni A., primary, Kirchhoff, Tomas, primary, Offit, Kenneth, primary, Devlin, Vincent, primary, Dutra-Clarke, Ana, primary, Piedmonte, Marion, primary, Rodriguez, Gustavo C., primary, Wakeley, Katie, primary, Boggess, John F., primary, Basil, Jack, primary, Schwartz, Peter E., primary, Blank, Stephanie V., primary, Toland, Amanda Ewart, primary, Montagna, Marco, primary, Casella, Cinzia, primary, Imyanitov, Evgeny, primary, Tihomirova, Laima, primary, Blanco, Ignacio, primary, Lazaro, Conxi, primary, Ramus, Susan J., primary, Sucheston, Lara, primary, Karlan, Beth Y., primary, Gross, Jenny, primary, Schmutzler, Rita, primary, Wappenschmidt, Barbara, primary, Engel, Christoph, primary, Meindl, Alfons, primary, Lochmann, Magdalena, primary, Arnold, Norbert, primary, Heidemann, Simone, primary, Varon-Mateeva, Raymonda, primary, Niederacher, Dieter, primary, Sutter, Christian, primary, Deissler, Helmut, primary, Gadzicki, Dorothea, primary, Preisler-Adams, Sabine, primary, Kast, Karin, primary, Schönbuchner, Ines, primary, Caldes, Trinidad, primary, de la Hoya, Miguel, primary, Aittomäki, Kristiina, primary, Nevanlinna, Heli, primary, Simard, Jacques, primary, Spurdle, Amanda B., primary, Holland, Helene, primary, Chen, Xiaoqing, primary, Platte, Radka, primary, Chenevix-Trench, Georgia, primary, and Easton, Douglas F., primary

Published
2023
Full Text
View/download PDF

49. Influence of genomic landscape on cancer immunotherapy for newly diagnosed ovarian cancer: biomarker analyses from the IMagyn050 randomized clinical trial

Author

Taşkıran, Çağatay (ORCID 0000-0002-0936-552X & YÖK ID 134190), Landen, Charles N.; Molinero, Luciana; Hamidi, Habib; Sehouli, Jalid; Miller, Austin; Moore, Kathleen N.; Bookman, Michael; Lindemann, Kristina; Anderson, Charles; Berger, Regina; Myers, Tashanna; Beiner, Mario; Reid, Thomas; Van Nieuwenhuysen, Els; Green, Andrew; Okamoto, Aikou; Aghajanian, Carol; Thaker, Premal H.; Blank, Stephanie V.; Khor, Victor K.; Chang, Ching-Wei; Lin, Yvonne G.; Pignata, Sandro, School of Medicine, Taşkıran, Çağatay (ORCID 0000-0002-0936-552X & YÖK ID 134190), Landen, Charles N.; Molinero, Luciana; Hamidi, Habib; Sehouli, Jalid; Miller, Austin; Moore, Kathleen N.; Bookman, Michael; Lindemann, Kristina; Anderson, Charles; Berger, Regina; Myers, Tashanna; Beiner, Mario; Reid, Thomas; Van Nieuwenhuysen, Els; Green, Andrew; Okamoto, Aikou; Aghajanian, Carol; Thaker, Premal H.; Blank, Stephanie V.; Khor, Victor K.; Chang, Ching-Wei; Lin, Yvonne G.; Pignata, Sandro, and School of Medicine

Abstract

Purpose: to explore whether patients with BRCA1/2-mutated or homologous recombination deficient (HRD) ovarian cancers benefitted from atezolizumab in the phase III IMagyn050 (NCT03038100) trial. Patients and Methods: patients with newly diagnosed ovarian cancer were randomized to either atezolizumab or placebo with standard chemotherapy and bevacizumab. Programmed deathligand 1 (PD-L1) status of tumor-infiltrating immune cells (IC) was determined centrally (VENTANA SP142 assay). Genomic alterations, including deleterious BRCA1/2 alterations, genomic loss of heterozygosity (gLOH), tumor mutation burden (TMB), and microsatellite instability (MSI), were evaluated using the FoundationOne assay. HRDwas defined as gLOH ? 16%, regardless of BRCA1/2 mutation status. Potential associations between progression-free survival (PFS) and genomic biomarkers were evaluated using standard correlation analyses and log-rank of Kaplan-Meier estimates. Results: among biomarker-evaluable samples, 22% (234/1,050) harbored BRCA1/2 mutations and 46% (446/980) were HRD. Median TMB was low irrespective of BRCA1/2 or HRD. Only 3% (29/1,024) had TMB ?10 mut/Mb, and 0.3% (3/1,022) were MSIhigh. PFS was better in BRCA2-mutated versus BRCA2-nonmutated tumors and in HRD versus proficient tumors. PD-L1 positivity (?1% expression on ICs) was associated with HRD but not BRCA1/2 mutations. PFS was not improved by adding atezolizumab in BRCA2-mutated or HRD tumors; there was a trend toward enhanced PFS with atezolizumab inBRCA1-mutated tumors. Conclusions: mostovariantumorshave lowTMBdespiteBRCA1/ 2mutations orHRD. NeitherBRCA1/2mutation norHRDpredicted enhanced benefit from atezolizumab. This is the first randomized double-blind trial in ovarian cancer demonstrating that genomic instability triggered by BRCA1/2 mutation or HRD is not associated with improved sensitivity to immune checkpoint inhibitors., This work was supported by F. Hoffmann-La Roche Ltd. The trial was sponsored, designed, and conducted by F. Hoffmann-La Roche/Genentech in collaboration with the Gynecologic Oncology Group Foundation (GOG-F) and the European Network for Gynaecological Oncological Trial Groups (ENGOT) according to what was subsequently described in 2019 as ENGOT model C. The sponsor (F. Hoffmann-La Roche/Genentech) was involved in data collection, analysis, and interpretation. Medical writing assistance was provided by Jennifer Kelly, MA (Medi-Kelsey Ltd, Ashbourne, UK), funded by F. Hoffmann-La Roche Ltd. No grant number is applicable. We thank the patients and their families and the investigators, study groups, and clinical sites for their contributions to the IMagyn050 trial and this analysis. IMagyn050/GOG 3015/ENGOT-OV39 is sponsored by F. Hoffmann-La Roche Ltd. The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results